ImmuCell director reports stock options holding

ImmuCell Corp. director Anthony DiMarco filed an initial ownership report showing a holding of non-qualified stock options.

Rhea-AI Filing Summary

ImmuCell Corp. director Anthony DiMarco filed an initial ownership report showing a holding of non-qualified stock options. These options cover 17,899 shares of common stock at an exercise price of $7.60 per share and expire on April 15, 2036.

The options vest over three years: 5,966 shares become exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares on April 15, 2029. This filing records DiMarco’s derivative equity position; it does not show any recent buy or sell transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider DiMarco Anthony

Role Director

Type	Security	Shares	Price	Value
holding	Non Qualified Stock Options (Right to buy)	--	--	--

Holdings After Transaction: Non Qualified Stock Options (Right to buy) — 17,899 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests as follows: 5,966 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares becoming exercisable on April 15, 2029.

Key Figures

Options underlying shares: 17,899 shares Exercise price: $7.60 per share Vesting 2027: 5,966 shares +3 more

6 metrics

Options underlying shares 17,899 shares Non-qualified stock options on ImmuCell common stock

Exercise price $7.60 per share Strike price for DiMarco’s non-qualified stock options

Vesting 2027 5,966 shares Become exercisable on April 15, 2027

Vesting 2028 5,966 shares Become exercisable on April 15, 2028

Vesting 2029 5,967 shares Become exercisable on April 15, 2029

Option expiration April 15, 2036 Expiration date of the non-qualified stock options

Key Terms

Non Qualified Stock Options (Right to buy), exercise price, vests, expiration date

4 terms

Non Qualified Stock Options (Right to buy) financial

"Security title is listed as Non Qualified Stock Options (Right to buy)."

exercise price financial

"The options have an exercise price of 7.6000 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests financial

"The stock option vests as follows: 5,966 shares becoming exercisable on each of April 15, 2027 and April 15, 2028."

expiration date financial

"The options have an expiration date of 2036-04-15."

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the ImmuCell (ICCC) Form 3 filing by Anthony DiMarco show?

The Form 3 shows director Anthony DiMarco holds non-qualified stock options covering 17,899 ImmuCell shares at $7.60 per share, expiring in 2036, with vesting spread across 2027, 2028, and 2029.

How many ImmuCell (ICCC) shares are covered by DiMarco’s stock options?

DiMarco’s options cover 17,899 shares of ImmuCell common stock. These are derivative rights, not currently owned shares, and become exercisable in three tranches from 2027 through 2029, subject to the vesting schedule disclosed.

What is the exercise price of Anthony DiMarco’s ImmuCell (ICCC) stock options?

The options have an exercise price of $7.60 per share. This means DiMarco can purchase ImmuCell common stock at $7.60 for each optioned share once the options vest and before they expire in 2036.

When do Anthony DiMarco’s ImmuCell (ICCC) stock options vest?

The options vest in three annual installments: 5,966 shares become exercisable on April 15, 2027, another 5,966 on April 15, 2028, and 5,967 on April 15, 2029, as described in the footnote.

When do Anthony DiMarco’s ImmuCell (ICCC) stock options expire?

The non-qualified stock options expire on April 15, 2036. After this expiration date, any unexercised options will lapse, meaning DiMarco can no longer use them to purchase ImmuCell common shares.

Does the ImmuCell (ICCC) Form 3 show any recent share purchases or sales by Anthony DiMarco?

The Form 3 does not show recent purchases or sales. It records an existing holding of non-qualified stock options, with 17,899 underlying shares, exercise price $7.60, and a defined vesting and expiration schedule.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/23/2026 - 12:29 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

DiMarco Anthony

(Last) (First) (Middle)

C/O IMMUCELL CORPORATION

56 EVERGREEN DRIVE

(Street)

PORTLAND MAINE 04103

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/15/2026

3. Issuer Name and Ticker or Trading Symbol
IMMUCELL CORP /DE/ [ ICCC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non Qualified Stock Options (Right to buy)	(1)	04/15/2036	Common Stock	17,899	$7.6	D

Explanation of Responses:

1. The stock option vests as follows: 5,966 shares becoming exercisable on each of April 15, 2027 and April 15, 2028, and 5,967 shares becoming exercisable on April 15, 2029.

Remarks:

The options were granted by the Issuer to compensate directors for services on the Issuer's board of directors.

	/s/ Timothy C. Fiori Attorney-in-Fact	04/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)